Ophthalmology HCP Resources
Discover our HCP resources to learn more about EYLEA® (aflibercept) 8 mg
Explore the resources outlined below to gain further insights into EYLEA® (aflibercept) 8 mg in neovascular (wet) age-related macular degeneration (nAMD) and visual impairment due to diabetic macular oedema (DMO).
Post-hoc analyses of the PULSAR and PHOTON data
The summary videos below highlight some of the key findings from the latest post-hoc analyses of the PULSAR (randomised, double-masked, non-inferiority, phase 3 trial in nAMD) 96-week data and the PHOTON (randomised, double-masked, non-inferiority, phase 2/3 trial in DMO) 156-week data.
Post-hoc analysis of the PULSAR fluid free status 96-week data
In this 4-minute summary video, Richard Gale presents the outcomes of fluid free status within the nAMD patient cohort of the PULSAR trial.
Prescribing information for EYLEA® (aflibercept) can be found here.
EYLEA® (aflibercept) 8 mg expert consensus pathways
The consensus pathways for optimising treatment with EYLEA 8 mg for nAMD and DMO were developed by an expert group of national medical retina thought leaders at two roundtable meetings organised and funded by Bayer. The pathways are now available to download using the link below.
Discover the EYLEA 8 mg expert consensus pathways and some top tips for their implementation in your clinic.
Please refer to the links below to hear from other experts who have used EYLEA 8 mg, and explore a variety of on-demand resources created in collaboration with both local and internationally recognised leaders in medical retina.
Abbreviations
DMO, diabetic macular oedema. HCP, healthcare professional. nAMD, neovascular (wet) age-related macular degeneration.
PP-EYL-GB-2866 | June 2025